Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
54
CORBF Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
-1.79%
Day range:
$0.95 - $0.95
52-week range:
$0.20 - $1.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.60x
P/B ratio:
0.17x
Volume:
45.2K
Avg. volume:
19.3K
1-year change:
-5.94%
Market cap:
$127.2M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CORBF
Global Cord Blood Corp.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.58 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$26M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CORBF
Global Cord Blood Corp.
|
$0.95 | -- | $127.2M | -- | $0.00 | 0% | 0.60x |
|
HCM
HUTCHMED (China) Ltd.
|
$13.52 | $22.58 | $2.3B | 5.04x | $0.00 | 0% | 3.91x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
$0.75 | -- | $8.2M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$16.91 | $26.00 | $284.6M | -- | $0.00 | 0% | 3.29x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$24.60 | -- | $12.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CORBF
Global Cord Blood Corp.
|
-- | -0.997 | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.509 | -- | 4.41x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 4.220 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 21.200 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CORBF
Global Cord Blood Corp.
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
Global Cord Blood Corp. vs. Competitors
-
Which has Higher Returns CORBF or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Global Cord Blood Corp.'s net margin of --. Global Cord Blood Corp.'s return on equity of -- beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood Corp.-- -- -- HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About CORBF or HCM?
Global Cord Blood Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.58 which suggests that it could grow by 67.05%. Given that HUTCHMED (China) Ltd. has higher upside potential than Global Cord Blood Corp., analysts believe HUTCHMED (China) Ltd. is more attractive than Global Cord Blood Corp..
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood Corp.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is CORBF or HCM More Risky?
Global Cord Blood Corp. has a beta of -0.693, which suggesting that the stock is 169.27% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.402%.
-
Which is a Better Dividend Stock CORBF or HCM?
Global Cord Blood Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood Corp. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or HCM?
Global Cord Blood Corp. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Global Cord Blood Corp.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Global Cord Blood Corp.'s price-to-earnings ratio is -- while HUTCHMED (China) Ltd.'s PE ratio is 5.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood Corp. is 0.60x versus 3.91x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood Corp.0.60x -- -- -- HCMHUTCHMED (China) Ltd.3.91x 5.04x -- --
-
Which has Higher Returns CORBF or HKPD?
Hong Kong Pharma Digital Technology Holdings Ltd. has a net margin of -- compared to Global Cord Blood Corp.'s net margin of --. Global Cord Blood Corp.'s return on equity of -- beat Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood Corp.-- -- -- HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- -
What do Analysts Say About CORBF or HKPD?
Global Cord Blood Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood Corp. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe Global Cord Blood Corp. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood Corp.0 0 0 HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 -
Is CORBF or HKPD More Risky?
Global Cord Blood Corp. has a beta of -0.693, which suggesting that the stock is 169.27% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CORBF or HKPD?
Global Cord Blood Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood Corp. pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or HKPD?
Global Cord Blood Corp. quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues of --. Global Cord Blood Corp.'s net income of -- is lower than Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of --. Notably, Global Cord Blood Corp.'s price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood Corp. is 0.60x versus 0.75x for Hong Kong Pharma Digital Technology Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood Corp.0.60x -- -- -- HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- --
-
Which has Higher Returns CORBF or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Global Cord Blood Corp.'s net margin of -28.82%. Global Cord Blood Corp.'s return on equity of -- beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood Corp.-- -- -- PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About CORBF or PRE?
Global Cord Blood Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 83.32%. Given that Prenetics Global Ltd. has higher upside potential than Global Cord Blood Corp., analysts believe Prenetics Global Ltd. is more attractive than Global Cord Blood Corp..
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood Corp.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is CORBF or PRE More Risky?
Global Cord Blood Corp. has a beta of -0.693, which suggesting that the stock is 169.27% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CORBF or PRE?
Global Cord Blood Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood Corp. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or PRE?
Global Cord Blood Corp. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Global Cord Blood Corp.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Global Cord Blood Corp.'s price-to-earnings ratio is -- while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood Corp. is 0.60x versus 3.29x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood Corp.0.60x -- -- -- PREPrenetics Global Ltd.3.29x -- $23.6M -$6.8M
-
Which has Higher Returns CORBF or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Global Cord Blood Corp.'s net margin of --. Global Cord Blood Corp.'s return on equity of -- beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood Corp.-- -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About CORBF or RGC?
Global Cord Blood Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood Corp. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Global Cord Blood Corp. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood Corp.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is CORBF or RGC More Risky?
Global Cord Blood Corp. has a beta of -0.693, which suggesting that the stock is 169.27% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CORBF or RGC?
Global Cord Blood Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood Corp. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or RGC?
Global Cord Blood Corp. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Global Cord Blood Corp.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Global Cord Blood Corp.'s price-to-earnings ratio is -- while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood Corp. is 0.60x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood Corp.0.60x -- -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
